Bücher
Monographien
Buchkapitel/Übersichtsarbeiten
Veröffentlichungen in Fachzeitschriften
Abstracts/Kongress-Beiträge: Poster-Präsentationen/Poster-Diskussionen
Wolf E (Hrsg), Mauss S, Jäger H. Die antiretrovirale Behandlung der HIV-Erkrankung. Thieme Verlag, Stuttgart, 1999.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 2014.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 2011.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 2008.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 2005.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 2004.
Hoffmann C, Wolf E., Jäger H, KIS – KIS OI Drugfinder. Opportunistische Infektionen bei HIV 2002.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 2001.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 1999.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 1998.
Wolf E., Jäger H, KIS – HIV Drugfinder. Antiretrovirale Therapie 1997
Wolf E, Braun P. Resistenzen und Tropismus. In: Hoffmann, Rockstroh. (Hrsg.). HIV 2013/14. Medizin Fokus Verlag, Hamburg, 2013/14
Wolf E, Braun P. HIV Resistance and Viral Tropim Testing. In: Hoffmann, Rockstroh. (Hrsg.). HIV 2012/13. Medizin Fokus Verlag, Hamburg, 2012/13
Wolf E, Braun P. Resistenzen und Tropismus. In: Hoffmann, Rockstroh. (Hrsg.). HIV 2012. Medizin Fokus Verlag, Hamburg, 2012
Wolf E, Braun P. Resistenzen und Tropismus. In: Hoffmann, Rockstroh. (Hrsg.). HIV 2011. Medizin Fokus Verlag, Hamburg, 2011
Wolf E, Braun P. Resistenzen. In: Hoffmann, Rockstroh. (Hrsg.). HIV 2010. Medizin Fokus Verlag, Hamburg, 2010.
Wolf E, Braun P. HIV Resistance Testing. In: Hoffmann, Rockstroh. (Hrsg.). HIV 2009. Medizin Fokus Verlag, Hamburg, 2009.
Wolf E, Braun P. Resistenzen. In: Hoffmann, Rockstroh. (Hrsg.). HIV 2009. Medizin Fokus Verlag, Hamburg, 2009.
Wolf E, Jaeger H. Country case study – The German situation. In: Zuniga, Whiteside, Ghaziani, Bartlett (Hrsg.). A decade of the HAART: Historical perspectives and future directions. Oxford University Press 2008.
Wolf E. Resistenzen. In: Hoffmann, Rockstroh, Kamps (Hrsg.). HIV.Net 2007. Steinhäuser Verlag, Wuppertal-Beyenburg, 2007.
Wolf E. HIV Drug Resistance 2005. In: Hoffmann, Rockstroh, Kamps (Editors). Available at: http://hivmedicine.com/textbook/authors/wolf.htm
Wolf E. Resistenzen. In: Hoffmann, Kamps (Hrsg.). HIV.Net 2004. Steinhäuser Verlag, Wuppertal-Beyenburg, 2004.
Wolf E. Resistenzen. In: Hoffmann, Kamps (Hrsg.). HIV.Net 2003. Steinhäuser Verlag, Wuppertal-Beyenburg, 2003.
Wolf E, Gersbacher E, Pascucci R, Moser-Jünemann Ch, Jaegel-Guedes E., Jäger H. 3 Monate Efavirenz im klinischen Alltag – Effektivität und Toxizität in der Firt-line- und Salvage-Therapie. In: Brockmeyer N.H., Brodt R., Hoffmann K., Reimann G., Stücker M., P. Altmeyer (Hrsg.) HIV-Infekt. Springer-Verlag, Berlin – Heidelberg, 2000.
Wolf E. Sequencing, Initialtherapie, Sekundär- und Folge- sowie Salvage-Therapie. In: Wolf E (Hrsg.), Mauss St, Jäger H. Die antiretrovirale Behandlung der HIV-Erkrankung. Thieme Verlag, Stuttgart, 1999.
Jäger H, Wolf E, Hammel G, Zwingers Th, Goetzenich A, Knechten H. Therapiestandard wird im Alltag nur mäßig umgesetzt. Deutsches Ärzteblatt 1999, 3A: 108 – 112.
Popescu M. u. Wolf E. HIV-1 RNA in fortgeschrittenen Stadien der HIV-1-Infektion. In: Jäger H. (Hrsg.) Virus Load und AIDS. Thieme Verlag, Stuttgart, 1997.
Wolf E, Wildegger A, Jäger H. Sample transportation on blue ice instead of dry ice – The impact on plasma HIV-1 RNA stability. In: Jäger H. (Hrsg.) Virus Load und AIDS. Thieme Verlag, Stuttgart, 1997.
Mauss S., Wolf E. Aktueller Stand der Therapie der HIV-Infektion (Antiretrovirale Therapie). Therapien bei AIDS. Loseblattsammlung der deutschen AIDS-Hilfe 1997.
Wolf E, Jaeger H. The Concept of the New ERA Study. MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:24-6. German.
Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C. HIV-associated lung cancer: survival in an unselected cohort. Scand J Infect Dis. 2013 Oct;45(10):766-72.
Dinkel A, Nather C, Jaeger H, Jaegel-Guedes E, Lahmann C, Steinke C, Wolf E, Ronel J. Stigmatization in HIV/AIDS: first German adaptation of the HIV-stigma scale (HSS-D). Psychother Psychosom Med Psychol. 2014 Jan;64(1):20-7. doi: 10.1055/s-0033-1341449. Epub 2013 May 15. German.
Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, Mayr C, Jaeger H, Pfaff H, Dupke S, Neumann A. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. Eur J Health Econ. 2013 Oct;14(5):799-808. doi: 10.1007/s10198-012-0425-4. Epub 2012 Sep 19.
Obermeier M, Pironti A, Berg T, Braun P, Däumer M, Eberle J, Ehret R, Kaiser R, Kleinkauf N, Korn K, Kücherer C, Müller H, Noah C, Stürmer M, Thielen A, Wolf E, Walter H. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology. 2012;55(2):102-7.
Knechten H, Stephan C, Mosthaf FA, Jaeger H, Carganico A, Lutz T, Schewe K, Mayr C, Wolf E, Wellmann E, Tappe A. The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. Eur J Med Res. 2011 Mar 28;16(3):93-100.
Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; Competence Network for HIV/AIDS. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection. 2011 Feb;39(1):3-12.
Glaubitz J, Sizmann D, Simon CO, Hoffmann KS, Drogan D, Hesse M, Lang G, Kroeh M, Simmler P, Dewald M, Haberhausen G, Lindauer A, Beyser K, Reber A, Baumeister A, Wolf E, Jaeger H, Babiel R. Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol. 2011 Feb;50(2):119-24.
Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, Walter H, Schmidt B, Arnold ML, Harrer EG, Kaiser R, Schweitzer F, Braun P, Reuter S, Jaeger H, Wolf E, Brockmeyer NH, Jansen K, Michalik C, Harrer T; German Competence Network for HIV/AIDS. Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition. J Acquir Immune Defic Syndr. 2011 Feb;56(2):109-17.
Wolf E, Blankenburg M, Bogner JR, Becker W, Gorriahn D, Mueller MC, et al. Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res 2010; 15(4):145-151.
Jaeger H, Wolf E, Simon CO, Babiel R. Traceability of 3 generations of nucleic acid amplification tests for quantitative HIV-1 RNA measurements to meet the WHO HIV-1 RNA International Standards. J Acquir Immune Defic Syndr 2010; 54(3):334-335.
Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, et al. Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2010; 54(1):51-58.
Stephan C, Jaeger H, Carganico A, Knecht G, Lutz T, Mayr C, Mosthaf FA, Koeppe S, Mueller M, Wolf E, Tappe A, Wellmann E, Knechten H. Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients. Eur J Med Res. 2010 Sep 24;15(9):369-76.
Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, Stoehr A, Koeppe S, Mayr C, Schewe K, Wolf E, Wellmann E, Tappe A. Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients. Infection. 2010 Apr;38(2):108-16.
Kastenbauer U, Wolf E, Kollan C, Hamouda O, Bogner JR. Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease. Eur J Med Res 2009; 14(6):244-249.
Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009; 14(7):277-283.
Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009 Apr;49(4):1141-50.
Erhardt A, Ludwig A, Brunetto M, Boemmel F, Wolf E, Goebel T, et al. HBV genotypes are the strongest predictor of response to interferon-alfa treatment: multivariate evaluation in 1229 hepatitis B patients [abstract no. 883] Hepatology 2008;48(Suppl 1):700A–701A.
Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther 2008; 13(8):1091-1095.
Jaeger H, Wolf E. [HIV eradication–facts and fiction]. MMW Fortschr Med 2008; 150 Spec No 1:72-73.
Hoffmann C, Ernst M, Meyer P, Wolf E, et al. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect 2007;13:510-5. Epub 2007 Feb 12.
Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8(5):679-688.
Hoffmann C, Stellbrink HJ, Dielschneider T, Degen O, Stoehr A, Knechten H, Wolf E, van Lunzen J.. Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis. Br J Haematol 2007;136:641-8.
Hoffmann C, Wolf E, Wyen C, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective. Leukemia & Lymphoma 2006, 47(9):1872-1880*
Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H. [High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr 2006; 131(34-35):1849-1852.
Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006;20:1951-4.
Wolf E, Hoffmann C, Procaccianti M, et al. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. Eur J Med Res 2005; 10: 56-62. Abstract: http://amedeo.com/lit.php?id=15817423
Fehr JS, Nicca D, Sendi P, Wolf E, et al. Starting or changing therapy-a prospective study exploring antiretroviral decision-making. Infection 2005, 33(4): 249-256
Hoffmann C, Tiemann M, Schrader C, Wolf E, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005; 106: 1762-9. Epub 2005 May 19. Abstract: http://amedeo.com/lit.php?id=15905193
Fehr JS, Nicca D, Sendi P, Wolf E, et al. Swiss HIV Cohot Study. Starting or changing therapy – a prospective study exploring antiretroviral decision-making. Infection 2005; 33: 249-56. Abstract: http://amedeo.com/lit.php?id=16091895
Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin´s disease. Br J Haematol 2004; 125: 455-62. Abstract: http://amedeo.com/lit.php?id=15142115
Mauss S, Scholten S, Wolf E, Berger F, Schmutz G, Jaeger H, et al. A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Med 2004; 5(1):15-17.
Hoffmann C, Wolf E, Fatkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17: 1521-9. Abstract: http://amedeo.com/lit.php?id=12824790
Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002; 3(1):49-55.
Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS Patients with Primary Central Nervous System Lymphoma Is Dramatically Improved by HAART-Induced Immune Recovery. AIDS 2001, 15: 2119-2127.
Wintergerst U, Kurowski M, Rolonski B, Müller M, Wolf E, Jaeger H, Belohradsky BH. Use of Saliva Specimens for Monitoring Indinavir Therapy in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy 2000, Sept, Vol. 44, No.9: 2572-2574.
Mauss S, Wolf E, Hans J. Changing incidence of mycobacterial diseases in German patients with HIV infection. AIDS Read 1999; 9: 386, 391-2. Abstract: http://amedeo.com/lit.php?id=12737129
Mauss S, Wolf E, Moser-Jünemann Ch, Jäger H. Reversal of protease inhibitor related visceral abdominal fat accumulation with recombinant human growth hormone. Annals.of Internal Medicine 1999. 131: No 4.
Mauss S, Wolf E, Moser-Jünemann Ch, Jäger H. Reversal of Visceral Abdominal Fat Accumulation Associated with the Use of HIV-Protease Inhibitors after Treatment with recombinant Human Growth Hormone. Annals of Internal Medicine 1999, 2: 313f.
Wintergerst U, Rolinski B, Sölder B, Bogner JR, Wolf E, Jäger H, Roscher AA, Belohradsky BH. Lack of Absorption of Didanosine after Rectal Administration in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy 1999, March : 699-701
Dietrich U, Raudonat I, Wolf E, Jager H, Husak R, Orfanos CE, et al. Indication for increasing prevalence of resistance mutations for protease inhibitors in therapy-naive HIV-1-positive German patients. AIDS 1999; 13(16):2304-2305
Mauss S, Wolf E, Jäger H. Impaired Glucose Tolerance in HIV-Positive Patients Receiving and Those Not Receiving Protease Inhibitors. Annals of Internal Medicine 1999, 2: 162-163
Dietrich U, Ruppach H, Gehring S, Knechten H, Knickmann M, Jäger H, Wolf E, Husak R, Orfanos CE, Brede HD, Rübsamen-Waigmann H, von Briesen H. Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors. AIDS 1997; 12: 1532-1533.*
Poppinger J, Wolf E, Morbach K, Pascucci R, Virgin G, Jaegel-Guedes E, Jäger H. Stavudine plus lamivudine versus zidovudine plus lamivudine in antiretroviral-naive HIV-positive patients. Antiretroviral Therapy 1997, 2 (Supplement 3): 109 – 111.
Tiller FW, Wolf E, Jägel-Guedes E, Jäger H. Application of Q-NASBATM for determining HIV-1 Viral Load in Human Plasma. Clinical Laboratory – Virology. 1995; 41: 769 – 772.
Wolf E, Balogh A, Baumann R, Denger R, Schoelzel S, Wuensche T, at al., and the 50/2010 study group. HDL in aging HIV+ patients treated with or without Nevirapine compared to HIV-negative patient groups – Results from the German 50/2010 Cohort Study. Abstrcat/Poster P-22.
Koegl C, Wolf E, Trapana G, Schlote F, Gospodinov B, Kuhlmann B, et al., and the 50/2010 study group. HIV+ and diabetes mellitus II not associated with depressive disorders in aging population. Results from the German 50/2010 cohort study. 1st International Workshop on HIV & Aging, Baltimore, MD, USA, 4-5 October 2010. Abstrcat/PosterP-05:
Mueck B, Koegl C, Wolf E, Karwat M, Baumgarten A, Rausch M, et al., and the 50/2010 study group. Sexual dysfunction in an aging HIV positive population compared to HIV negative control groups. Results from the German 50/2010 cohort study. 1st International Workshop on HIV & Aging, Baltimore, MD, USA, 4-5 October 2010. Abstract/Oral presentation O-10.
Wolf E, Eger J, Balogh A, Goelz J, Brust J, Rockstroh J, et al. and the NoVi Study Group. CD4 Slope in HIV Elite and Viremic Controllers – Data from the German NoVi Cohort. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract WEAA0105, oral presentation.
Wolf E, Balogh A, Koegl, Baumann R, Denger R, Schoelzel S, et al., and the 50/2010 study group. Excess Cardiovascular Risk in HIV+ Patients Aged over 50 – Results from the German 50/2010 Cohort Study in Aging Populations of HIV+ and HIV- Patients. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract WEPE0043
Koegl C, Wolf E, Mueck B, Schlote F, Gospodinov B, Kuhlmann B, et al., and the 50/2010 study group Depressive Disorders are Associated with Socio-Economic Factors and Not with Chronic Diseases like HIV + or Diabetes Mellitus – Results from the German 50/2010 Cohort Study in Aging Populations of HIV+ and HIV– Patients. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract WEPE0041
Mauss S, Wolf E, Berger F, Koegl C, Hegener P, Schmutz G, Henke J, Jaeger H. Are there clinical consequences of low level viremia after introducing a more sensitive real-time PCR assay? XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract TUPE0110
Mueck B, Koegl C, Wolf E, Karwat M, Baumgarten A, Rausch M, et al., and the 50/2010 study group. Is Sexual Dysfunction Associated with HIV Infection or Age? Results from the German 50/2010 Cohort Study in Aging Populations of HIV+ and HIV- Patients. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract WEPE0044
Knechten H, Wiesmann F, Wolf E, Scholten S, Schnaitmann E, Trein A, et al. Clinical outcome of HIV tropism testing and Maraviroc regimens – 48 weeks follow-up. XVIII Int. AIDS Conf., Vienna, Austria, 18-23 July 2010. Abstract THPE0142
Koegl C, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger , Koeppe S, Lutz T, Mueller M, Schmidt W, Trein A, Wolf E, Petry R and Stellbrink HJ. Similar virological response in Art-naïve HIV+ patients with low CD4 cell counts initiating a Lopinavir/Ritonavir-based regimen. 48 week data from the German STAR and STELLA cohorts. 12th European AIDS Conference (EACS), Cologne, Germany, 11 – 14 November 2009. Abstract PE 7.9/20
Koegl C., Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger H, Koeppe S, Lutz T, Mueller M, Schmidt W, Trein A, Wolf E. , Koenig B and Stellbrink HJ. No subjective or objective gender differences in ART-naïve patients initiating a Lopinavir/Ritonavir-based regimen. 48 week data from the German STAR and STELLA cohorts. 12th European AIDS Conference (EACS), Cologne, Germany, 11 – 14 November 2009. Abstract PE 7.9/19
Koegl C, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger H, Lutz T, Mueller M, Schmidt W, Trein A, Pauli R, Wolf E, Petry R, Stellbrink HJ. Kivexa versus Truvada: Similar virological outcomes in ART-naive patients starting a Lopinavir/Ritonavir-based regimen. 48-week-data from the STAR and STELLA Cohorts. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19 – 22 July 2009. Abstract MOPEB055
Wolf E, Braun P, Schneider L, Knechten H, Karwat M, Balogh A, Ehret R, Mosthaf F, Ulmer A, Jaeger H. Predictors for CXCR4-Tropism: CD4-Nadir and the Use of the Enhanced Sensitivity (ES) Trofile Assay. 1. Deutsch-Österreichisch-Schweizerischer AIDS-Kongress – SÖDAK 2009. St. Gallen. Schweiz. 24. – 27. Juni 2009. Abstract P483
Wolf E, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger H, Lutz T, Mueller M, Schmidt W, Trein A, Pauli R, Koegl C, Petry R, Stellbrink HJ. Kivexa versus Truvada: Similar virological outcomes in ART-naive patients starting a Lopinavir/Ritonavir-based regimen. 48 week data from the STAR and STELLA Cohorts. 1. Deutsch-Österreichisch-Schweizerischer AIDS-Kongress – SÖDAK 2009. St. Gallen. Schweiz. 24. – 27. Juni 2009. Abstract P415
Wolf E, Trein A, Schmidt W, Baumgarten A, Jaeger H Stellbrink HJ. Similar virological response rates for ART-naive subjects starting KVX + LPV/r or TVD + LPV/r Data from the prospective non-interventional STAR Cohort. Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 9. – 13. November 2008. Abstract P007
Wolf E, Stoll M, Becker-Andre M, et al. Prospective HLA-B*5701 screening for abacavir hypersensitivity saves costs. XVII International AIDS Conference, Mexico City, Mexico, August 03 – 08, 2008. Abstract THPE 0192.
Wolf E, Becker-Andre M, Stoll M, Bogner J, Becker W, Gorriahn D, Jaeger H, Welte R, Baudewig M, Walli R. Cost-savings of prospective HLA-B+ 5701 screening prior to ABC/3TC FDC use in Germany. KIT 2008 – 9. Kongress für Infektiologie und Tropenmedizin. Innsbruck. 27. Feb.- 1. März 2008. Abstract P212.
Stellbrink HJ, Schewe K, Hoffmann C, Wolf E. Is there a harmless level of plasma viremia in untreated HIV infection? CD4+ T cells in the long-term follow-up of elite controllers and controls. 15th Conference on Retroviruses and Opportunistic Infections. February 3-6, 2008. Boston. Abstract 351.
Balogh A, Koegl C, Wolf E, Mueck B, Jaegel-Guedes E, Jaeger H. Aging with HIV – New Challenges in the Medical Care of HIV-Positive Women and Men. XVII International AIDS Conference, Mexico City, Mexico, 3. – 8. August 2008. Abstract THPE0906
Koegl C, Wolf E, Eberhard A, Eger J, von Krosigk A, Jaegel-Guedes E, Jaeger H. Switching from Lopinavir/r capsules to Lopinavir/r tablets. Is there an improvement of gastrointestinal complaints? XVII International AIDS Conference, Mexico City, Mexico, 3. – 8. August 2008. Abstract TUPE0088
Kastenbauer U, von Krosigk A, Wolf E, Jaeger H. Lung-cancer in HIV/AIDS: rising incidence, poor survival and impact of HAART. XVII International AIDS Conference, Mexico City, Mexico, 3. – 8. August 2008. Abstract THPE0233
Jaeger H, Eger J, Koegl C, Wolf E, Balogh A, Jaegel-Guedes E, Naik N, Gilada I. Healthy Unrest: Canova stimulates CD4 cells in ART treated virologically suppressed but immunologically unresponsive HIV patients. XVII International AIDS Conference, Mexico City, Mexico, 3. – 8. August 2008. Abstract LBPE1130
Koegl C, Wolf E, von Krosigk A, Eger J, Eberhard A, Gunturu G, Meurer A, Kastenbauer U, Jaegel-Guedes E, Jaeger H. Normalization of quality of life after starting an antiretroviral treatment in naive HIV-patients. XVII International AIDS Conference, Mexico City, Mexico, 3. – 8. August 2008. Abstract THPE0843
Eger J, Wolf E, Gölz J, Brust J, Ulmer A, Nzimegne-Gölz S, Mosthaf F, Vogel M, Rockstroh J, Leistner I, Mayr C, Carganico A, Mueller M, Jaeger H. Untreated HIV patients with undetectable virus – What happens to the CD4 cells. Deutsch-Österreichischer AIDS-Kongress. Frankfurt a. M.. 27.-30. Juni 2007. Abstract B.26
Mueck B, Balogh A.-M., Wolf E, Koegl C, Jaegel-Guedes E, Jaeger H. Berufstätigkeit und Bildungsniveau bei HIV-infizierten Frauen und Männern in Deutschland. Deutsch-Österreichischer AIDS-Kongress. Frankfurt a. M.. 27.-30. Juni 2007. Abstract A.45
Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H and the Prime-DAG and Ac-DAG Study Group. No Benefit from Early Treatment in Primary HIV-Infection. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles. 25.-28. Februar 2007. Abstract 125LB
Knechten H, Carganico A, Glaessel F, Jaeger H, Knecht G, Koeppe S, Lutz T, Mayr C, Mosthaf F, Schewe K, Schuler C, Stephan C, Wolf E, Steinmueller J, Waesle B, Tappe A, Wellmann E. The rainbow cohort: Saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naive patients initiating treatment with saquinavir 500mg film-coated tablets – 24 week interim results from Germany. Deutsch-Österreichischer AIDS-Kongress. Frankfurt a. M.. 27.-30. Juni 2007. Abstract D.5
Koegl C, Wolf E, Eberhard A, Jaegel-Guedes E, Jaeger H. Fosamprenavir/ritonavir (FPV/r): decrease of liver enzymes in patients co-infected with hepatitis C. Eighth International Congress on Drug Therapy in HIV Infection. Glasgow. 12.-16. November 2006. Abstract P108
Wolf E, Gunturu G, Koegl C, Jaegel-Guedes E, Jaeger H. Tenofovir (TDF) versus non-TDF-containing ART: renal safety in daily practice. Eighth International Congress on Drug Therapy in HIV Infection. Glasgow. 12.-16. November 2006. Abstract P153
Vogel M, Wolf E, Ummard K, Koegl C, Wasmuth J-C, Bicim G, Moll A, Jaeger H, Rockstroh JK. Injection site reactions (ISR) and success of HAART influence continued use of enfuvirtide (T20). Eighth International Congress on Drug Therapy in HIV Infection. Glasgow. 12.-16. November 2006. Abstract P183
Wolf E, Koegl C, Theobald T, Jaegel-Guedes E, Jaeger H. Nevirapine-associated hepatotoxicity: no increased risk for females or high CD4 count in a single-centre HIV cohort. 46th annual ICAAC. San Francisco. 27.-30. September 2006. Abstract H-1063
Koegl C, Wolf E. Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H, and the Prime-DAG and Ac-DAG Study Group. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstract MOPE0060
Jaeger H, Wolf E, Jaegel-Guedes E, Chantratita W, Schumacher W. HIV real-time PCR assay COBAS AmpliPrep/COBAS TaqMan HIV-1 test in comparison to the Bayer bDNA assay versant HIV-1 RNA v3.0 and the Roche COBAS amplicor HIV monitor test v1.5. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstract MOPE0156
Wolf E, Laubereau B, Gunturu G, Koegl C, Jaegel-Guedes E, Jaeger H. Electronic diaries: a new tool to measure social factors, clinical conditions, and health-related quality of life (HRQL) in HIV-patients on HAART. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstract TUPE0660
Goelz J, Wolf E, Moll A, Koegl C, Jaeger H. Single agent HAART with lopinavir/r (LPV/r) in ART-naive and pre-treated HIV-1-infected patients. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstract THPE0134
Vogel M, Wolf E, Ummard K, Kögl C, Wasmuth J-C, Däumer M, Kupfer B, Kaiser R, Moll A, Jäger H, Rockstroh JK. Die Wertigkeit des genotypischen Interpretationssystems Virco TYPE HIV-1 auf das virologische Ansprechen bei Patienten mit 3-Klassen-Versagen. 11. Münchner AIDS Tage. München. 3.-5. Februar 2006. S. 43-45
Wolf E, Walter H, Eckerlein B, Koegl C, Jaegel-Guedes E, Jaeger H. Development of De Novo PI-Resistance in Lopinavir/Ritonavir-Monotherapy. 3rd IAS Conference on Pathogenesis and Treatment. Rio de Janeiro. 24.-27. Juli 2005. Abstract WePe4.4C08
Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Knechten H, Jaeger H. Virus control after early treatment of primary HIV-infection. 10. Deutscher und 16. Österreichischer AIDS-Kongress. Wien. 1.-4. Juni 2005. Abstract V8
Wolf E, Kaliebe T, Ranneberg B, Koegl C, Schewe K, Jaegel-Guedes E, Jaeger H. Renal safety of Tenofovir (TDF) in clinical practice – a pooled analysis of two German cohorts. 10. Deutscher und 16. Österreichischer AIDS-Kongress. Wien. 1.-4. Juni 2005. Abstract P154
Koegl C, Wolf E, Ruemmelein N, Morbach K, Buchberger A, Wandel J, Jaeger H. Large Nevirapine cohort: 7% discontinuation due to Hepatotoxicity. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract WePeB5933
Jaegel-Guedes E, Wolf E, Ruemmelein N, Postel N, Koegl C, Buchberger A, Wandel J, Weisser S, Jaeger H. Incidence of Tenofovir-related nephrotoxicity in a large outpatient cohort. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract WePeB5937
Postel N, Wolf E, Koegl C, Buchberger A, Ruemmelein N, Wandel J, Jaegel-Guedes E, Jaeger H. Anti-HBV Vaccination in HIV-Infection: Successful only with CD4 cell count >500/µl combined with a viral load below 1000 cps/ml. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract MoPeB3330
Wolf E, Koegl C, Hoffmann C, Ruemmelein N, Postel N, Jaegel-Guedes E, Jaeger H. Low dose stavudine: less side effects but as effective as standard dose. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract WePeB5861
Wolf E, Ruemmelein N, Hoffmann C, Buchberger A, Kuschak D, Kögl C, Tiller FW, Postel N, Jaegel-Guedes E, Jaeger H. Week 2 – Nevirapine (NVP) plasma levels are associated with NVP-related toxicity. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract TuPeB4640
Ruemmelein N, Wolf E, Koegl C, Wadel J, Jaegel-Guedes E, Jaeger H. Primary HIV-infection: lower viral setpoint in early treated patients. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract TuPeB4592
Jaeger H, Jessen H, Goetzenich A, Koegl C, Schewe K, Rausch M, Wolf E, Goelz J, Knechten H. Primary HIV-infection: clinical symptoms are correlated with early outcome in non-treatment group. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract TuPeB4590
Koegl C, Buchberger A, Morbach K, Postel N, Ruemmelein N, Wolf E, Wandel J, Eberhard A, Jaegel-Guedes E, Jaeger H. Lipids or Virus. Atazanavir as effective as Lopinavir. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract TuPeB4557
Wolf E, Laubereau B, Wandel G, Gunturu G, Ruemmelein N, Buchberger A, Jaegel-Guedes E, Jaeger H. Electronic diaries: Daily assessment of quality of life (QoL) shows high depression in HIV/AIDS. XV. International AIDS Conference. Bangkok. 11.-16. Juli 2004. Abstract MoPeD3884
Hoffmann C, Wolf E, Faetkenheuer G, Wyen C, Stellbrink HJ, van Lunzen J, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hoelzer D, Horst HA. The short and intensive B-all protocol is a highly effective regimen in patients with AIDS-associated Burkitt or Burkitt-like Lymphoma. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco. 8.-11. Februar 2004. Abstract Nr. 787
Postel N, Wolf E, Ruemmelein N, Buchberger A, Jaegel-Guedes E, Jaeger H. Universal protease associated mutations (UPAMS) are responsable for Lopinavir/Ritonavir (LPV/R) – based HAART-failure – analysis of 79 patients based on genotyping. 9th European AIDS Conference. Warschau. 25.-29. Oktober 2003. Abstract Nr. 3.4/9
Mauss S, Holm S, Wolf E, Kuhlmann B, Bellmunt A, Jaeger H, Berger F, Schmutz G. Tenofovir in clinical practice – first, second, third line? 9th European AIDS Conference. Warschau. 25.-29. Oktober 2003. Abstract Nr. 7.4/17
Koegl C, Wolf E, Postel N, Buchberger A, Ruemmelein N, Jaegel-Guedes E, Jaeger H. Low dose Stavudine: As effective as standard dose but less side effects. 9th European AIDS Conference. Warschau. 25.-29. Oktober 2003. Abstract Nr. 9.8/5
Fehr J, Nicca D, Spirig R, Wagels T, Kiss A, Bregenzer T, Vernazza P, Sendi P, Wolf E, Jäger H, Battegay M and the Swiss HIV Cohort Study. Starting or changing HAART: readiness of patients. 9th European AIDS Conference. Warschau. 25.-29. Oktober 2003. Abstract Nr. 10.1/3
Hoffmann C, Corzillius M, Wolf E, Fätkenheuer G, Woehrmann A, Stoehr A, Plettenberg A, Lorenzen T, Stellbrink HJ, van Lunzen J, Jäger H, Horst HA. AIDS-assoziierte Burkitt-Lymphome – Erfahrungen mit dem B-ALL-Protokoll. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 22
Postel N, Rümmelein N, Wolf E, Gersbacher E, Buchberger A, Kögl C, Morbach K, Hoffmann C, Jägel-Guedes E, Jäger H. Erfahrungen mit Lopinavir/ritonavir (LPV/r) bei 300 HIV-infizierten Patienten über einen Zeitraum von 12 Monaten. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 62
Koegl C, Gersbacher E, Buchberger A, Wolf E, Ruemmelein N, Postel N, Morbach K, Jagel-Guedes E, Jaeger H. Klassenbester? PI, NNRTI, NRTI im Vergleich bei therapie-naiven Patienten. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 68
Jaeger H, Koegl C, Wolf E, Jessen H, Schewe C, Goelz J, Hoffmann C, Fenske S, Knechten H. Prime DAG – erste Ergebnisse zu 91 Patienten mit primärer HIV-Infektion. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 83
Ruemmelein N, Wolf E, Hoffmann C, Koegl C, Jaegel-Guedes E, Jaeger H. Antiretrovirale Therapie (ART) und Strukturierte Therapieunterbrechungen (STI) bei der primären HIV-Infektion (PHI). 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 85
Wolf E, Hoffmann C, Ruemmelein N, Buchberger A, Kuschak D, Koegl C, Tiller FW, Postel N, Jaegel-Guedes E, Jaeger H. Therapeutisches Drug-Monitoring (TDM) von Nevapirin (NVP) und das Auftreten NVP-assoziierter Nebenwirkungen. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 118
Mauss S, Scholten S, Wolf E, Berger F, Schmutz G, Jaeger H, Kurowski M, Rockstroh JK. Kann Ritonavir 200 mg bid die Interaktion von Lopinavir und Amprenavir verhindern? 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 125
Postel N, Wolf E, Buchberger A, Rümmelein N, Weisser S, Jägel-Guedes E, Jäger H. Impferfolg gegen Hepatitis B-Virus bei HIV-Infizierten ist abhängig von Viruslast und CD4-Zellzahl. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 161
Hoffmann C, Wolf E, Jägel-Guedes E, Wildegger A, Jäger H. Persistenz genotyppischer Resistenzmutationen nach Transmission multiresistenter Viren. 9. Deutscher und 14. Österreichischer AIDS-Kongress. Hamburg. 14.-17. Mai 2003. Abstract Nr. 191
C. Hoffmann*, E. Wolf, G. Fätkenheuer, T. Buhk, A. Stoehr, A. Plettenberg, T. Lorenzen, H.J. Stellbrink, U. Siebert, K. Schewe, J. van Lunzen, H.A. Horst, H. Jäger. AIDS-Related Lymphoma (ARL): Outcome Is Strongly Predicted by Efficacy of Highly Active Antiretroviral Therapy (HAART). 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Feb 24-27, 2002, Poster # 619 W.
2001
Wolf, E., Gersbacher, E., Schardt, J., et. al. Long-term effects of treatment interruptions (TI): 18-month evaluation of a controlled trial in > 300 HIV+ patients. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, Dec. 16-19, 2001, abstract 1910.
Hoffmann C, Mayer W, Wolf E, et al. Enhancement of HIV Specific Immune Response during Structured Treatment Interruptions (STI) in Chronic HIV-Infection Depends on Baseline Viral Load. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, Dec. 16-19, 2001, abstract 1910.
Wolf E, Hoffmann C, Gersbacher E , Schardt J , Mueller S, Mosthaf F, Ulmer A, Procaccianti M, Jägel-Guedes E, Jäger H. Langzeiteffekte von Therapiepausen (TP): 18-Monats-Auswertung einer kontrollierten, prospektiven Studie an über 300 HIV-Patienten.8th German AIDS Conference July 4-7, 2001 Eur J Med Res 6 (Suppl I) 2001: 39.
Hoffmann C, Tabrizian S, Wolf E, Buhk T, Eggers C, Stellbrink HJ , Stoehr A, Plettenberg A, Horst HA , Jaegel-Guedes E, Jaeger H, Rosenkranz T. Survival of AIDS Patients with Primary Central Nervous System Lymphoma Is Dramatically Improved by HAART-Induced Immune Recovery. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Feb 4-8, 2001, Abstract-Nr. J19e/ Poster-Nr. 590.
Hoffmann C, Wolf E, Mueller S, Ulmer A, Procaccianti M, Mosthaf F, Schardt J, Gersbacher E, Moser-Juenemann C, Buchberger A, Jaegel-Guedes E, Jaeger H. Drug Holidays in HIV+ Patients – Clinical Issues. Fifth International Congress on Drug Therapy in HIV Infection, Oktober 22-26, 2000, Glasgow, Poster/Abstract-Nr. 68.
Mauss S, Corzillius M, Wolf E, Schwenk A, Jaeger H, Goelz J, Knechten H, Adam A, Goetzenich A. Risk factors for HALS (HIV-associated lipodystrophy syndrome) in patients with uniform duration of ART. 2nd International Workshop on Adverse drug Reactions and Lipodystrophy in HIV, Toronto, 2000, Sept. 13-15. Poster/Abstract-Nr. P68.
Mauss S, Corzillius M, Wolf E, Schwenk A, Jaeger H, Goelz J, Knechten H, Adam A, Goetzenich A. Prevalence and Risk factors for the HIV-Associated Lipodystrophy Syndrome (HALS) in Patients Beiing 3 Years on ART. 40th Intersience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, 2000, Sept. 17-20. Poster/Abstract-Nr. 1287
Hoffmann C, Jaegel-Guedes E, Wolf E, Gersbacher E, Mueller S, Pascucci R, Buchberger A, Moser-Juenemann C, Jaeger H. PI-sparing in ART-naive HIV+ patients: Efficacy and Tolerability of d4T/ddI plus Efavirenz (EFV) vs d4T/ddI plus Abacavir (ABC). 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeB4185.
Wolf E, Jaegel-Guedes E, Mueller S, Pascucci R, Moser-Juenemann C, Buchberger A, Hoffmann C, Jaeger H. Estradiol levels and lipodystrophy in HIV+ men. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000. Poster/ Abstract-Nr. WePpB1382.
Jaegel-Guedes E, Richter D, Leiberich P, Lydtin D, Wolf E, Morbach K, Pascucci R, Buchberger A, Moser-Juenemann C, Jaeger H. Chronic fatigue – a growing problem in ART- treated HIV+ patients. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeC4458.
Jaeger H, Wolf E, Schardt J, Ulmer A, Procaccianti M, Mosthaf F, Mueller S, Moser-Juenemann C, Pascucci R, Buchberger A, Hoffmann C, Jaegel-Guedes E. Drug Holidays (DH): Impact on VL, CD4 Cells and Clinical Outcome in HIV+ patients. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeB4207.
Jaegel-Guedes E, Wolf E, Gersbacher E, Lydtin D, Mueller S, Pascucci R, Moser-Juenemann C, Hoffmann C, Jaeger H. HU (hydroxyurea) vs PI, both combined with d4T+ddI, in ART- naive HIV+ patients. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. ThPeB5060.
Jaeger H, Gersbacher E, Wolf E, Hoffmann C, Pascucci R, Moser-Juenemann C, Jaegel-Guedes E. Efavirenz (EFV) versus Nevirapine (NVP): Efficacy and effects on blood lipids in PI-sparing regimens. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeB4182.
Hoffmann C, Jaegel-Guedes E, Wolf E, Gersbacher E, Pascucci R, Moser-Juenemann C, Jaeger H. PI to Efavirenz (EFV) switch effect on lipids in HIV-positive patients. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. WePeB4185.
Wolf E, Gersbacher E, Buchberger A, Eckerlein B, Wildegger A, Tiller FW, Graebnitz F, Mueller S, Moser-Juenemann C, Pascucci R, Hoffmann C, Jaegel-Guedes E, Jaeger H. Genotypic antiretroviral resistance and clinical outcome: data from a community-based outpatient HIV practice. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. TuPeB3281.
Mauss S, Corzillius M, Wolf E, Schwenk A, Jaeger H, Goelz J, Knechten H, Adam A, Goetzenich A. Risk factors for HALS (HIV-associated lipodystrophy syndrome) in patients with uniform duration of ART. 13th International AIDS Conference, Durban, South Africa, July 9-14,2000, Poster/Abstract-Nr. ThPpB1486
Jaegel-Guedes E, Wolf E, Gersbacher E, Pascucci R, Moser-Jünemann Ch, Buchberger A, Jäger H. ddI/d4T plus hydroxyurea – An alternative to a PI-containing triple regimen in ART-naive HIV+ patients? 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 563.
Jäger H, Pascucci R, Wolf E, Gersbacher E , Buchberger A, Moser-Jünemann Ch, Jaegel-Guedes E. PI-sparing in ART-naive HIV-Patients: D4T/DDI plus Efavirenz (EFV) vs. D4T/DDI plus Abacavir (ABC). 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 562.
Kurowski M, Wintergerst U, Müller M, Rolinski B, Jäger H, Wolf E. Relation of saliva and plasma levels in patients treated with ritonavir and indinavir. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 833.
Moser-Jünemann Ch, Wolf E, Pascucci R, Jaegel-Guedes E, Jäger H. Avascular necrosis of the femoral head in an HIV+man associated more likely with hyperlipidemia than with corticoid treatment. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 1075.
Dietrich U, Raudonat I, Knickmann M,Knechten H, Wolf E, Jaeger H, Husak R, von Briesen, Ruppach H, Immelmann A. Evidence for transmission of HIV-1 variants with resistance mutations for protease inhibitors in Germany. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Poster/Abstract-Nr. 1002.
Corzillius M., Schwenk A., Wolf E., Goetzenich A., Mauss S., Beckmann R., Jaeger H., Breuer P., Knechten H., Locher L., Adam A. Does phycisian assessment match patient perception of body changes in lipodystrophy? 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999, Late-Breaker Abstract-Nr. 1220
Goetzenich M., Schwenk A., Corzillius M., Wolf E., Mauss S., Beckmann R., Jaeger H., Breuer P., Knechten H., Locher L., Adam A. Impact of lipodystrophy on quality of life. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27,1999 Late-Breaker Abstract-Nr. 1211.
Wolf E, Gersbacher E, Buchberger A, Pascucci R, Moser-Jünemann Ch, Lydtin D, Jägel-Guedes E, Jäger H. Use of Ritonavir in Salvage Therapy. 39th ICAAC, San Francisco, 26. – 29. September 1999. Poster/Abstract I-212.
Wolf E, Jäger H., Gersbacher E, Pascucci R, Moser-Jünemann Ch, Jaegel-Guedes E. 3 Monate Efavirenz im klinischen Alltag – Effektivität und Toxizität in der Firt-line- und Salvage-Therapie. 7. Deutscher AIDS-Kongreß, Essen, 2. – 6. Juni 1999. NA 35.3, Abstract F1189.
Ronel J, Mitzdorf U., Wolf E., Jägel-Guedes E., Jäger H. Psychosoziale Korrelate der HIV-Krankheitsprogression. 7. Deutscher AIDS-Kongreß, Essen, 2. – 6. Juni 1999. NA 19.3, Abstract F1056.
Jäger H, Wolf E, Mosthaf F, Wildegger A, Ulmer A, Schuster D, Becker W. Clinical relevance of undetectable HIV RNA levels measured by the ultrasenisitive bDNA techology 3.0. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, 13. Januar – 4. Februar 1999, Poster Präsentation (via Eva Wolf) Session 23/ Abstract-Nr. 174
Mauss St, Wolf E, Moser-Jünemann C, Jäger H. Successful treatment of PI-induced visceral abdominal fat accumulation with R-human growth hormone. 4th International Congress on Drug Therapy in HIV Infection Glasgow, 8. – 12. November 1998, Poster/Abstract. AIDS 1999, 12: S53-S53.
Wolf E, Hammel G, Zwingers T, Goetzenich A, Knechten H, Jäger H. D4T plus 3TC or AZT plus 3TC – Viral Load Suppression After 12 Months. 12th World AIDS Conference. Genf, 28. Juni – 3. Juli 1998, Poster/Abstract-Nr. 32321
Wolf E, Mauss S, Pascucci R, Immelmann A, Dietrich U, Jägel-Guedes E, Jäger H. Impact of Protease Gene Mutations on Virological Response to Nelfinavir. 12th World AIDS Conference. Genf, 28. Juni – 3. Juli 1998, Poster/Abstract-Nr. 41222
Stroeer S, Jäger H, Hammel G, Wolf E, Knechten H, Schloer St. Comparison of three commercial kits for quantification of HIV-1-RNA in an open, prospective study in Germany (ART 96). 12th World AIDS Conference Genf, 28. Juni – 3. Juli 1998, Abstract-Nr. 60504
Fuchs A, Wolf E, Scheider A, Kampik A, Jäger H. Significance of CD4 Cell Count and HIV Viral Load on CMV-Retinitis Treated With an Implant. 12th World AIDS Conference. Genf, 28. Juni – 3. Juli 1998, Poster/Abstract-Nr. 32243
Ronel J, Mitzdorf U, Wolf E, Jägel-Guedes E, Jäger H. Psychosocial Factors Affecting the Progression of the HIV-Disease in Homosexual Men. 12th World AIDS Conference. Genf, 28. Juni – 3. Juli 1998, Poster/Abstract-Nr. 13340
Jäger H, Wolf E, Hammel G, Zwingers T, Graafmans J, Goetzenich A, Knechten H. HAART is not Hard Enough – Virological Failure after 12 months of Treatment in ART-Naive HIV+ Patients. 12th World AIDS Conference. Genf, 28. Juni – 3. Juli 1998, Poster/Abstract-Nr. 32319
Jägel-Guedes E, Wolf E, Virgin G, Pascucci R, Mauss S, Jäger H, D4T/ddI Plus Hydroxyurea – An Alternative to a PI Containing Triple Regimen in ART-Naive HIV+ Patients? 12th World AIDS Conference. Genf, 28. Juni – 3. Juli 1998, Poster/ Abstract-Nr. 32315
Mauss S, Wolf E, Pascucci R, Virgin G, Jägel-Guedes E, Jäger H. Risk Factors For Diabetes Mellitus in HIV Positive Patients. 12th World AIDS Conference. Genf, 28. Juni – 3. Juli 1998, Poster/Abstract-Nr. 12377
Mauss S, Wolf E, Jägel-Guedes E, Pascucci R, Jäger H. Decreasing Incidence of Mycobacterial Diseases in HIV+ Patients. 12th World AIDS Conference. Genf, 28. Juni – 3. Juli 1998, Poster/Abstract-Nr. 22166
Pascucci R, Sonnenberg-Schwan U, Wolf E, Jägel-Guedes E, Jäger H. A Model of Care for HIV-Positive Pregnant Women. I Convegno Nazionale L’A.I.D.S: e la Donna, Neapel, 26. -28. März 1998, Poster/Abstract-Band S. 179
Wolf E, Zwingers T, Jäger H. AZT+3TC versus d4T+3TC in treatment naive HIV-patients. 6th European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, 11. – 15. Oktober 1997. Poster/Abstract Nr. 370.
Fuchs A, Wolf E, Scheider A, Jäger H, Klauß V, Kampik A. Ganciclovir-Implantat vs Systemic Therapy: CMV-Retinitis with AIDS. 2nd International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics. Berlin, 20. – 23. September 1997
Poppinger J, Wolf E, Jäger H. Viruslast und MAC Inzidenz. 6. Münchner AIDS-Tage, München, 4. – 6. Juli 1997. In: Jäger (Hrsg.). AIDS – Neue Perspektiven – Therapeutische Erwartungen – Die Realität 1997. Ecomed Verlag, Landsberg/Lech 1997.
Virgin G, Jägel-Guedes E, Pascucci R, Poppinger J, Wolf E, Gorriahn D, Ryttig KR, Schiotz J, Jäger H. Tolerability, Immunostimulating and Antiviral Efficacy of the Peptide FR-91 in the Treatment of HIV Positive Patients. A Phase II Study. 6. Münchner AIDS-Tage. München, 4. – 6. Juli 1997. In: Jäger (Hrsg.). AIDS – Neue Perspektiven – Therapeutische Erwartungen – Die Realität 1997. Ecomed Verlag, Landsberg/Lech 1997.
Poppinger J, Wolf E, Pascucci R, Jägel-Guedes E, Jäger H. Cortison in der HIV Therapie. 6. Münchner AIDS-Tage. München, 4. – 6. Juli 1997. In: Jäger (Hrsg.). AIDS – Neue Perspektiven – Therapeutische Erwartungen – Die Realität 1997. Ecomed Verlag, Landsber/Lech 1997.
Wolf E, Gersbacher E, Poppinger J, Virgin G, Pascucci R, Jägel-Guedes E, Jäger H. CMV Infection – A Systemic Clinical Disease? 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22. – 26. Januar 1997.
Pascucci Rita, Wolf E, Virgin G, Poppinger J, Jäger H. Community Based Oberservations Support Virostatic Efficacy of d4T in Advanced HIV-Patients. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. We.B.3120.
Popescu M, Wolf E, Jägel-Guedes E, Jäger H. HIV-1 RNA Viral Load Measurements. Are they a Good Predictor of Mortality in CDC-AIDS-Patients? XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Th.B. 4298.
Wolf E, Virgin G, Dietrich U, Immelmann A, Jägel-Guedes E, Jäger H, Poppinger J. The Impact of Genotype Drug Resistance on Viral Burden. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. Th.B.4343.
Glaessel F, Wolf E, Buschmans E, Stauder G, Poppinger J, Jägel-Guedes E, Jäger H. Efficacy and Toxicity of Hydrolytic Enzymes in the Treatment of HIV Infection. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. Th.B.4100.
Virgin G, Wolf E, Zander K, v. Steinbuechl N, Gorriahn D, Bauer G, Albrecht H, Poppinger J, Jägel-Guedes E, Jäger H. Efficacy of Peptide T in the Palliative Treatment of HIV Related Symptoms. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. Th.B.180.
Wildegger A, Maier O, Förtsch M, Wolf E, Virgin G, Jäger H. Sample Transportation on Blue Instead of Dry Ice – The Impact on Plasma HIV-1 RNA Stability. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. Th.B.4339.
Jägel-Guedes Eva, Pascucci R, Wolf E, Gorriahn D, Jäger H. Toxicity, Immunestimulating and Antiretroviral Efficacy of the Peptide FR-91 in the Treatment of HIV Positive Patients. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996
Jäger H, Virgin G, Pascucci R, Poppinger J, Jägel-Guedes E, Wolf E. Virostatic Efficacy of AZT+3TC in Advanced HIV Patients with Previous Exposure to Antiretroviral Drugs – Community Based Data. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. We.B.3121.
Zink Th, Virgin G, Wolf E, Poppinger J, Jägel-Guedes E, Jäger H. High Self Reported Alcohol Consumption is Not Correlated With Shorter Life Expectancy in AIDS Patients. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. Th.B.4280.
Woelken Michael, Poppinger J, Wolf E, Jägel-Guedes E, Jäger H. Oral Retarded Morphine in Pain Management in HIV Patients. XI. International Conference on AIDS. Vancouver, Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. Th.B.4115.
Poppinger J, Wolf E, Virgin G, Jägel-Guedes E, Jäger H. Impact of Palliative Corticoid Therapy in Advanced HIV-1-RNA in Plasma. XI. International Conference on AIDS, Vancouver. Kanada, 7. – 12. Juli 1996. Poster/Abstract Nr. Th.B.195.
Ruppach H, Knechten H, Knickmann M, Jäger H, Jägel-Guedes E, Wolf E, Rübsamen-Waigmann H, Dietrich H. Hinweise für eine Veränderung der HIV-Epidemie in westlichen Ländern: Zunahme der HIV-1 Subtypen E und C unter den HIV-1 Neuinfektionen in Deutschland. 5. Münchner AIDS-Tage. München, 26.- 28. Januar 1996. In: Jäger (Hrsg.). AIDS und HIV-Infektionen in Klinik und Praxis – Management der Erkrankung. Ecomed Verlag, Landsberg/Lech 1996.
Poppinger J, Wolf E, Jägel-Guedes E, Jäger H. Klinische Diagnostik der MAC – Erfahrungen in einer HIV-Schwerpunktpraxis. 5. Münchner AIDS-Tage. München,26.- 28. Januar 1996. In: Jäger (Hrsg.). AIDS und HIV-Infektionen in Klinik und Praxis – Management der Erkrankung. Ecomed Verlag, Landsberg/Lech 1996.
Schlenzig C, Poppinger J, Wolf E, Jäger H. Efficacy and Toxicity of ddI and AZT Monotherapy Versus Combined and Alternating AZT/ddI Regimes. X. International Conference on AIDS. Yokohama, Japan, 7. – 12. August 1994. PBO261.
Wolf E, Hartl H, Poppinger J, Jägel-Guedes E, Jäger H. G-CSF Given to Severly Ill Patients in a Community-based Setting. Filgastrim Improves White Blood Cell Counts in HIV-Related Granulocytopenia – No Lasting Decline in Thrombocytes. IX. International Conference on AIDS. Berlin, Juni 1993. Poster/Abstract Nr. PO-B32-2246.
Jägel-Guedes E, Schmuck B, Poppinger J, Wolf E, Jäger H. How Much Does It Cost? A Clinicians View of Drug Expenses in HIV-Disease. IX. International Conference on AIDS. Berlin, Juni 1993. Poster/Abstract Nr. PO-D28-4214.
